Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients

Haematologica

Volumn 92, Issue 1, 2007, Pages 106-109

  Pelizzari, Anna Maria ^a   Drera, Monica ^b   D'Adda, Mariella ^a   Ungari, Marco ^b   Marocolo, Daniela ^a   Facchetti, Fabio ^b   Bellotti, Daniela ^b   Barlati, Sergio ^b   Rossi, Giuseppe ^a  

^a Divisione di Ematologia   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute myeloid leukemia; Elderly; G CSF; Therapy

Indexed keywords

CORTICOSTEROID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW CELL; BONE PAIN; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPLASIA; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPLASIA; KARYOTYPE; LOW DRUG DOSE; MALE; NEUTROPHIL COUNT; PROGNOSIS; THROMBOCYTE COUNT; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; FILGRASTIM; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846913001     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10185     Document Type: Article

References (20)

1. Ferrara F, Annunziata M, Copia C, Magrin S, Mele G, Mirto S. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998;83:126-31.
2. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, et al. Survival of elderly patients with acute myeloid leukemia. Haematologica 2004;89:296-302.
3. Rossi G, Pelizzari AM, Bellotti D, Tonelli M, Barlati S. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia 2000;14:636-41.
4. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001;97: 3589-95.
5. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
6. Nimubona S, Grulois I, Bernard S, Drénou B, Godard M, Fauchet R, et al. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases. Leukemia 2002;16:1871-3.
7. Bishop MR, Tarantolo SR, Pavletic ZS, Lynch JC, Morris ME, Zacharias D, et al. Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol 2000;18:2269-72.
8. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17: 835-49.
9. Cheson BD, Bennet JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4.
10. Pellegrini W, Facchetti F, Marocolo D, Pelizzari AM, Capucci A, Rossi G. Expression of CD34 by megakaryocytes in myelodysplastic syndromes. Haematologica 2000;85:1117-8.
11. Bennett JM, Catovsky D, Daniel MT, Handrin G, Galton DAG, Gralnik HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:626-9.
12. Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, et al. Granulocyte colony-stimulating factor and the risk or secondary myeloid malignancy after etoposide treatment. Blood 2003;101:3862-7.
13. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. The EORTC/GIMEMA Leukemia Groups. Blood 2005;106:27-34.
14. Löwenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349:743-52.
15. National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria version 2.0. http://ctep.cancer.gov/forms/ctcv2nom-4-30-99- final3.pdf
16. Yanigasawa K, Yano A, Takada K, Yasukawa M, Fujita S. Increase of erythropoiesis and thrombopoiesis, and induction of remission by granulocyte colony-stimulating factor (G-CSF) in a patient with hypoplastic leukemia. Leukemia 1994;8:1249-51.
17. Piccaluga PP, Martinelli G, Malagola M, Rondoni M , Bianchini M, Visani G, et al. Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature. Haematologica 2003;88:ECR 28.
18. Marcucci G, Mròzek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. J Clin Oncol 2004;22:2410-8.
19. Pan L, Teshima T, Hill GR, Bungard D, Brinson YS, Reddy VS, et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood 1999; 93:4071-8.
20. Godwin JE, Kopecky JK, Head DR, Willman CL, Leith CP, Hynes HE, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998; 91:3607-15.